Anti-HLA DR7+DR beta抗体[TAL 13.1] (ab20185)

概述

  • 产品名称Anti-HLA DR7+DR beta抗体[TAL 13.1]
  • 描述
    小鼠单克隆抗体[TAL 13.1] to HLA DR7+DR beta
  • 经测试应用适用于: WB, ELISA, Flow Cytmore details
  • 种属反应性
    与反应: Human
  • 免疫原

    Tissue/ cell preparation (Human): L cells transfected with the human HLA-DRB1*0701 gene

性能

  • 形式Liquid
  • 存放说明Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
  • 存储溶液Preservative: None
    Constituents: PBS
  • Concentration information loading...
  • 纯度IgG fraction
  • 克隆单克隆
  • 克隆编号TAL 13.1
  • 骨髓瘤P3-NS1/1-Ag4-1
  • 同种型IgM
  • 研究领域

应用

Our Abpromise guarantee covers the use of ab20185 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
WB Use at an assay dependent concentration. Predicted molecular weight: 30 kDa.
ELISA Use at an assay dependent concentration.
Flow Cyt Use at an assay dependent concentration. ab91545-Mouse monoclonal IgM, is suitable for use as an isotype control with this antibody.

靶标

  • 相关性Human Leukocyte Antigens are highly polymorphic proteins that are involved in the presentation of antigens to the T cell receptor. There are two classes of HLA antigens, class I (HLA A, HLA B and HLA C) and class II (HLA D).
  • 细胞定位Type I membrane protein
  • 数据库链接
  • 别名
    • DR7 antibody

Anti-HLA DR7+DR beta antibody [TAL 13.1] (ab20185)参考文献

This product has been referenced in:
  • Heyes JM  et al. A DR7 specific monoclonal antibody TAL13.1, raised against a transfectant detects IL-4 upregulated antigen on peripheral B-lymphocytes. Eur J Immunogenet 18:379-91 (1991). Read more (PubMed: 1722998) »

See 1 Publication for this product

Product Wall

There are currently no Abreviews or Questions for ab20185.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"